Physician profile
Millicent C Bennett
NPI 1134826787
$3,654.55
in general payments reported to CMS, 2019-2025
27 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $786 · 2024: $1,664 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $429.09 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $392.13 | 2023-2025 | |
| Amgen INC. | $331.97 | 2023-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $280.98 | 2023-2025 | Farxiga, Airsupra |
| Tris Pharma INC | $237.13 | 2023-2025 | Dyanavel Xr |
| Pfizer INC. | $203.06 | 2023-2025 | |
| Abbott Laboratories | $200.11 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $185.13 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $173.47 | 2023-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $166.68 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $107.47 | 2024 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $82.60 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $35.65 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lundbeck LLC | $34.20 | 2023 | Vyepti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $32.31 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $24.38 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $21.98 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $20.39 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2025 | Rexulti |
| Seqirus USA INC | $18.81 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Esperion Therapeutics, INC. | $18.38 | 2025 | Nexletol |
| Eisai INC. | $16.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2025 | Jardiance |
| Ibsa Pharma INC. | $14.50 | 2025 | Licart, Tirosint, Flector |
| Scilex Pharmaceuticals INC. | $13.97 | 2023 | Ztlido |
| Phathom Pharmaceuticals, INC. | $13.17 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.